Health-related quality of life and its influencing factors among lung cancer patients receiving immune checkpoint inhibitors : A cross-sectional study
Copyright © 2024 Elsevier Ltd. All rights reserved..
PURPOSE: The aim of this study was to examine the level of health-related quality of life (HRQOL) of lung cancer patients receiving immune checkpoint inhibitors (ICIs) and analyze its influencing factors.
METHOD: A cross-sectional study was conducted. From April 2022 to March 2023, 560 lung cancer patients receiving ICIs at three medical bases in Guangzhou, China were recruited using a convenient sampling method. A general information questionnaire, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), the Social Support Rating Scale (SSRS) and the Medical Coping Modes Questionnaire (MCMQ) were used for collecting data on sociodemographic and clinical characteristics, HRQOL, social support and medical coping mode. A descriptive analysis was conducted to describe HRQOL. Multiple regression analysis was applied to determine the factors influencing HRQOL.
RESULTS: For lung cancer patients receiving ICIs, the mean score of HRQOL was 59.21 ± 19.86. Multivariate analysis indicated that acceptance-resignation coping mode (β = -0.37, P < 0.01), Eastern Cooperative Oncology Group (ECOG) score (β = -0.35, P < 0.01), combination of chemotherapy and/or bevacizumab (β = -0.14, P < 0.01), and subjective support (β = 0.07, P = 0.04) all contributed to 42.7% of the variance in HRQOL of the patients receiving ICIs.
CONCLUSIONS: It is imperative to address and resolve the HRQOL issue for lung cancer patients receiving ICIs. The findings suggest nurse practitioners should be aware of a variety of factors that influence HRQOL and provide tailored inventions to patients as early as possible to help them achieve better HRQOL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:68 |
|---|---|
| Enthalten in: |
European journal of oncology nursing : the official journal of European Oncology Nursing Society - 68(2024) vom: 15. Feb., Seite 102507 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Hong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Health-related quality of life |
|---|
| Anmerkungen: |
Date Completed 19.02.2024 Date Revised 19.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejon.2024.102507 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367100215 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367100215 | ||
| 003 | DE-627 | ||
| 005 | 20240219232001.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240115s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejon.2024.102507 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1299.xml |
| 035 | |a (DE-627)NLM367100215 | ||
| 035 | |a (NLM)38219475 | ||
| 035 | |a (PII)S1462-3889(24)00005-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Hong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Health-related quality of life and its influencing factors among lung cancer patients receiving immune checkpoint inhibitors |b A cross-sectional study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.02.2024 | ||
| 500 | |a Date Revised 19.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Ltd. All rights reserved. | ||
| 520 | |a PURPOSE: The aim of this study was to examine the level of health-related quality of life (HRQOL) of lung cancer patients receiving immune checkpoint inhibitors (ICIs) and analyze its influencing factors | ||
| 520 | |a METHOD: A cross-sectional study was conducted. From April 2022 to March 2023, 560 lung cancer patients receiving ICIs at three medical bases in Guangzhou, China were recruited using a convenient sampling method. A general information questionnaire, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), the Social Support Rating Scale (SSRS) and the Medical Coping Modes Questionnaire (MCMQ) were used for collecting data on sociodemographic and clinical characteristics, HRQOL, social support and medical coping mode. A descriptive analysis was conducted to describe HRQOL. Multiple regression analysis was applied to determine the factors influencing HRQOL | ||
| 520 | |a RESULTS: For lung cancer patients receiving ICIs, the mean score of HRQOL was 59.21 ± 19.86. Multivariate analysis indicated that acceptance-resignation coping mode (β = -0.37, P < 0.01), Eastern Cooperative Oncology Group (ECOG) score (β = -0.35, P < 0.01), combination of chemotherapy and/or bevacizumab (β = -0.14, P < 0.01), and subjective support (β = 0.07, P = 0.04) all contributed to 42.7% of the variance in HRQOL of the patients receiving ICIs | ||
| 520 | |a CONCLUSIONS: It is imperative to address and resolve the HRQOL issue for lung cancer patients receiving ICIs. The findings suggest nurse practitioners should be aware of a variety of factors that influence HRQOL and provide tailored inventions to patients as early as possible to help them achieve better HRQOL | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Health-related quality of life | |
| 650 | 4 | |a Immune checkpoint inhibitors | |
| 650 | 4 | |a Lung cancer | |
| 650 | 4 | |a Medical coping mode | |
| 650 | 4 | |a Social support | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 700 | 1 | |a Dong, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Tiantian |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Siying |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Yalan |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Shan |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Qiujuan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yumei |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Yuan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of oncology nursing : the official journal of European Oncology Nursing Society |d 2000 |g 68(2024) vom: 15. Feb., Seite 102507 |w (DE-627)NLM126097704 |x 1532-2122 |7 nnns |
| 773 | 1 | 8 | |g volume:68 |g year:2024 |g day:15 |g month:02 |g pages:102507 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejon.2024.102507 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 68 |j 2024 |b 15 |c 02 |h 102507 | ||